Clinical Trial Detail

NCT ID NCT02267863
Title A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Aptose Biosciences Inc.
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

APTO-253

Age Groups: adult senior

No variant requirements are available.